Clinical Trial News and Research

RSS

FDA grants 510(K) clearance to market Vitala Continence Control Device

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today that the U.S. Food and Drug Administration has granted 510(K) clearance to market Vitala, an exceptionally innovative, non-intrusive ostomy continence control device, for people with an end colostomy.

9 Apr 2010

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Catalyst Pharmaceutical Partners, Inc. today announced that on Friday April 16th, Eugene C. Somoza, MD, PhD, University of Cincinnati College of Medicine and VA Medical Center, Cincinnati, OH will present a paper he authored along with Charles Gorodetzky, MD, PhD, Douglas Winship and Peggy Somoza, entitled: "A Multi-Site, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Vigabatrin (VGB) for Treating Cocaine Dependence"

9 Apr 2010

Tβ4 therapy for ocular disorders closer to reality

RegeneRx Biopharmaceuticals, Inc. announced today that Tβ4, a synthetic version of a naturally occurring peptide that is the basis for the company's product candidates, will be the subject of three poster presentations at the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) to be held in Fort Lauderdale, Florida from May 2-6, 2010.

9 Apr 2010

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

Researchers at the Cedars-Sinai Heart Institute have found in animals that infusing cardiac-derived stem cells with micro-size particles of iron and then using a magnet to guide those stem cells to the area of the heart damaged in a heart attack boosts the heart's retention of those cells and could increase the therapeutic benefit of stem cell therapy for heart disease.

9 Apr 2010

PAREXEL International experts to present key industry topics during conference in Orlando

Experts from PAREXEL International Corporation, a leading global biopharmaceutical services provider, will present key industry topics during the 19th Annual Partnerships in Clinical Trials Conference, to be held April 12 – 14, 2010 in Orlando, Florida.

From Parexel 9 Apr 2010

World's largest autism science and advocacy organization awards 16 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 16 new research grants totaling $5,223,743 over the next three years.

9 Apr 2010

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

A five-year, $3.7 million clinical trial will investigate how to balance the benefits and risks of warfarin, a drug that helps prevent potentially deadly blood clots.

9 Apr 2010

Idaho man fourth in country to receive Levacor- VAD implant

After receiving only the fourth U.S. implant of a new-generation, Utah-made ventricular assist (VAD ) device, an Idaho man with heart failure is looking forward to resuming an active life following an operation on March 17 at University of Utah Hospital.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Idera Pharmaceuticals, Inc. today presented data from a preclinical study evaluating the mechanism of action of a Toll-like Receptor (TLR) antagonist in a preclinical model of atherosclerosis. The presentation entitled "A novel antagonist of TLR7 and TLR9 exerts anti atherogenic effects in ApoE-/- mouse model of atherosclerosis" (abstract P259) was made by Idera scientists at the American Heart Association conference "Arteriosclerosis, Thrombosis and Vascular Biology 2010 Scientific Sessions" being held April 8-10 in San Francisco, CA.

9 Apr 2010

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Nicotine withdrawal can cause dangerous agitation in intensive care patients. Researchers writing in BioMed Central's open access journal Critical Care found that, compared to non-smokers, agitated smokers were more likely to accidentally remove tubes and catheters, require supplemental sedative, analgesic or anti-psychotic medications, or need physical restraints.

9 Apr 2010

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

Keryx Biopharmaceuticals, Inc. announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of patients with refractory advanced colorectal cancer.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Fate Therapeutics, Inc. announced today a definitive agreement to acquire Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Verio Therapeutics is advancing the work of several of Canada's leading stem cell scientists, including Michael Rudnicki, Ph.D., FRSC, and Lynn Arthur Megeney, Ph.D., who have made breakthrough discoveries relating to muscle and pancreatic regeneration.

9 Apr 2010

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

Cell Therapeutics, Inc. today announced that it had received a Complete Response Letter from the U.S. Food and Drug Administration regarding its New Drug Application for Pixuvri™ (pixantrone dimaleate) for relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL").

9 Apr 2010

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

ReVision Optics, a leading company in the research, development and manufacture of custom optical products to correct and maintain vision, announced today that it has begun its US clinical trial of the PresbyLens® corneal inlay. The clinical trial will evaluate the PresbyLens® corneal inlay for the correction of presbyopia, the age-related loss of near vision. The study began on April 6th with the treatment of three subjects by clinical investigator Dr. Stephen Slade of the Slade & Baker Vision Center in Houston, Texas.

9 Apr 2010

Æterna Zentaris commences perifosine Phase 3 registration trial

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced the initiation of a Phase 3 registration clinical trial with perifosine (KRX-0401) ), the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, for the treatment of refractory advanced colorectal cancer.

9 Apr 2010

BioClinica WebSend system that accelerates image collection for clinical studies released

BioClinica, Inc., a global provider of clinical trial management services, today announced the release of BioClinica WebSend, a system that simplifies and accelerates image collection for clinical studies. WebSend transfers and tracks medical images in real-time, offering key benefits over the standard manual transport methods commonly used in imaging trials, including faster delivery of image data, enhanced data quality with fewer site queries, and reduced cost.

From Clario 8 Apr 2010

Study shows benefits of oxytocin nasal spray in children with ASD

Autism spectrum disorders are developmental disorders usually diagnosed in childhood. Children with ASDs have impairments in social interactions and communication, and a tendency towards repetitive behaviors. A hallmark of autism is a difficulty in understanding and reciprocating the emotion of others.

8 Apr 2010

Clinical Trial News and Research

FDA grants 510(K) clearance to market Vitala Continence Control Device

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Catalyst Pharmaceutical Partners' vigabatrin data to be presented at 41st ASAM conference

Tβ4 therapy for ocular disorders closer to reality

Magnetic targeting may enhance effectiveness of stem cell therapies for heart injuries

PAREXEL International experts to present key industry topics during conference in Orlando

World's largest autism science and advocacy organization awards 16 new research grants

Five-year, $3.7M trial evaluates customized warfarin dosage based on patient genetics

Idaho man fourth in country to receive Levacor- VAD implant

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Idera Pharmaceuticals' TLR antagonists exert anti atherogenic effects in preclinical model of atherosclerosis

Dangerous agitations: Nicotine replacement therapy needs to be tested in ICU setting

Keryx Biopharmaceuticals commences Phase 3 registration clinical trial for perifosine

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Fate Therapeutics to acquire Ottawa biotechnology company Verio Therapeutics

Cell Therapeutics receives FDA Complete Response Letter for Pixuvri NDA

ReVision Optics initiates US clinical trial of PresbyLens corneal inlay

Æterna Zentaris commences perifosine Phase 3 registration trial

BioClinica WebSend system that accelerates image collection for clinical studies released

Study shows benefits of oxytocin nasal spray in children with ASD

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer